The nascent field of AllergoOncology

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1355-1357

  Jensen Jarolim, Erika ^a   Pawelec, Graham ^b  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

AllergoOncology; Cancer; IgE; Immunotherapy; Symposium in Writing

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; ALLERGEN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FOLATE BINDING PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN E ANTIBODY; UNCLASSIFIED DRUG;

ALLERGY; ATOPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DESENSITIZATION; DISEASE MODEL; DRUG TOLERANCE; EFFECTOR CELL; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; MEDICAL LITERATURE; NONHUMAN; ONCOGENE; ONCOLOGY; PEER REVIEW; POINT MUTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; NEOPLASMS;

EID: 84866538501     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1315-4     Document Type: Review

References (10)

1. Turner MC (2011) Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. Online FirstTM 20 Dec 2011. doi: 10.1007/s00262-011-1180-6
2. Dalton DK, Noelle RJ (2012) The roles of mast cells in anticancer immunity. Cancer Immunol Immunother. Online FirstTM 18 Apr 2012. doi: 10.1007/s00262-012-1246-0
3. Platzer B, Dehlink E, Turley SJ, Fiebiger E (2011) How to connect an IgE-driven response with CTL activity? Cancer Immunol Immunother. Online FirstTM 31 Oct 2011. doi: 10.1007/ s00262-011-1127-y
4. Gatault S, Legrand, F, Delbeke M, Loiseau S, Capron M (2012) Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother. Online FirstTM 17 June 2012. doi: 10.1007/ s00262-012-1288-3
5. Daniels TR, Martínez-Maza O, Penichet ML (2011) Animal models for IgE-meditated cancer immunotherapy. Cancer Immunol Immunother. Online FirstTM 22 Dec 2011. doi: 10.1007/ s00262-011-1169-1
6. Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, Dodev T, Koers A, Blower PJ, Corrigan C, Beavil AJ, Spicer JF, Nestle FO, Gould HJ (2011) Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother. Online FirstTM 2 Dec 2011. doi: 10.1007/s00262-011-1162-8
7. Spillner E, Plum M, Blank S, Miehe M, Singer J, Braren I (2012) Recombinant IgE antibody engineering to target EGFR. Cancer Immunol Immunother. Online FirstTM 7 June 2012. doi: 10.1007/s00262-012-1287-4
8. Castells M, Sancho-Serra MC, Simarro M (2012) Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother. Online FirstTM 11 May 2012. doi: 10.1007/s00262-012- 1273-x
9. Bluth MH (2011) IgE and chemotherapy. Cancer Immunol Immunother. Online FirstTM 2 Dec 2011. doi: 10.1007/s00262-011-1170-8
10. Mechtcheriakova D, Svoboda M, Meshcheryakova A, Jensen-Jarolim E (2012) Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation and cancer. Cancer Immunol Immunother. Online FirstTM 23 Apr 2012. doi: 10.1007/ s00262-012-1255-z